AZAiwen Zheng

Aiwen Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aiwen Zheng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine learning modeling and analysis of prognostic hub genes in cervical adenocarcinoma: a multi target therapy for enhancement in immunosurveillance

    by Madiha Jabeen Abbasi, Rashid Abbasi, ShuPeng Wu, Belal Bin Heyat, Ding Xianfeng, Huijie Jia, Aiwen Zheng

    Endocervical adenocarcinoma (ECA) the fatal and intrusive subtype of cervical carcinoma is on rise from the last decade. Its improper detection leads to worst clinical outcomes that urges the discovery of novel biomarkers. Therefore, we proposed insilico and invitro based approches to identify key genes that could be used as potential targeted therapies. RNA-seq and gene expression data was operated via R-programming that identified 11,592 differential expressed genes which are mainly enriched in metabolic pathways, chemical carcinogenesis-receptor activation, amoebias, MAPK and PI3K-AKT signaling pathway. Clustering modules and hub genes were retrieved to design network of immune cells with varying expression using multiple statistical algorithms. The Drugs targeting hub genes were determined from Drug gene interaction database which was further categorized for docking and dynamics based simulations. Results indicate high binding affinity of Imatinib compound into active pockets of BIRC5 which is confirmed by cell viability lab experiment. Current study demonstrates novel biomarkers and therapeutic drugs for in depth understanding of endocervical carcinogensis.


  • Open Access

    Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms

    by Ping Liu, Minya Yao, Yu Gong, Yunjie Song, Yanan Chen, Yizhou Ye, Xiao Liu, Fugen Li, Hua Dong, Rui Meng, et al.

    With the great progress made recently in next generation sequencing (NGS) technology, sequencing accuracy and throughput have increased, while the cost for data has decreased. Various human leukocyte antigen (HLA) typing algorithms and assays have been developed and have begun to be used in clinical practice. In this study, we compared the HLA typing performance of three HLA assays and seven NGS-based HLA algorithms and assessed the impact of sequencing depth and length on HLA typing accuracy based on 24 benchmarked samples. The algorithms HISAT-genotype and HLA-HD showed the highest accuracy at both the first field and the second field resolution, followed by HLAscan. Our internal capture-based HLA assay showed comparable performance with whole exome sequencing (WES). We found that the minimal depth was 100X for HISAT-genotype and HLA-HD to obtain more than 90% accuracy at the third field level. The top three algorithms were quite robust to the change of read length. Thus, we recommend using HISAT-genotype and HLA-HD for NGS-based HLA genotyping because of their higher accuracy and robustness to read length. We propose that a minimal sequence depth for obtaining more than 90% HLA typing accuracy at the third field level is 100X. Besides, targeting capture-based NGS HLA typing may be more suitable than WES in clinical practice due to its lower sequencing cost and higher HLA sequencing depth.


  • Open Access

    Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience

    by Gu Jin, Chunyang Wang, Dongdong Jia, Wenkang Qian, Chunming Yin, Danhua Wang, Quanyu Yang, Tao Li, Aiwen Zheng

    Background: Next generation sequencing (NGS) has systematically investigated the genomic landscape of soft tissue sarcoma (STS) in Western patients, but few reports have described the utility of NGS in identifying pathogenic and targetable mutations in Asian patients. Methods: We review our single center experience of identifying the genomic profile and feasible genetic mutations in 65 Chinese patients with STS by NGS. Results: On average, 3.35 mutations were identified per patient (range, 0-28), and at least one mutation could be detected in 95.4% (62/65) of patients. TP53, MDM2, CDK4, KDR, and NF1 were the most frequent mutation genes in Chinese STS patients. Actionable mutations were discovered in 36.9% (24/65) of patients, and clinical benefit was achieved in 4 patients treated with corresponding molecular targeted therapies. Conclusions: Our study describes the mutation profile of Chinese STS patients by a single center experience. Some patients have achieved improved clinical outcomes by adopting treatment based on the results of genetic testing. NGS may affect clinical decision-making as a routine clinical test for patients with STS.


  • Lesion Segmentation in Ultrasound Using Semi-Pixel-Wise Cycle Generative Adversarial Nets

    by Jie Xing, Zheren Li, Biyuan Wang, Yuji Qi, Bingbin Yu, Farhad Ghazvinian Zanjani, Aiwen Zheng, Remco Duits, Tao Tan

    Breast cancer is the most common invasive cancer with the highest cancer occurrence in females. Handheld ultrasound is one of the most efficient ways to identify and diagnose the breast cancer. The area and the shape information of a lesion is very helpful for clinicians to make diagnostic decisions. In this study we propose a new deep-learning scheme, semi-pixel-wise cycle generative adversarial net (SPCGAN) for segmenting the lesion in 2D ultrasound. The method takes the advantage of a fully convolutional neural network (FCN) and a generative adversarial net to segment a lesion by using prior knowledge. We compared the proposed method to a fully connected neural network and the level set segmentation method on a test dataset consisting of 32 malignant lesions and 109 benign lesions. Our proposed method achieved a Dice similarity coefficient (DSC) of 0.92 while FCN and the level set achieved 0.90 and 0.79 respectively. Particularly, for malignant lesions, our method increases the DSC (0.90) of the fully connected neural network to 0.93 significantly (p < 0.001). The results show that our SPCGAN can obtain robust segmentation results. The framework of SPCGAN is particularly effective when sufficient training samples are not available compared to FCN. Our proposed method may be used to relieve the radiologists' burden for annotation.